Status: Recruiting
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
The purpose of this research study is to see if it is feasible to combine a fixed dose of pembrolizumab and a daily dose of oral lenvatinib, along with daily treatments of an abbreviated course of pelvic external beam radiation therapy, to support cancer cells in multiplying and spreading to other body sites.
Participants needed: 18
Trial details
Phase: Phase 1Age: 18+Biological sex: FemaleType: InterventionalSponsor: Aaron WolfsonUpdated: Feb 24, 2026Locations: 1
Eligibility criteria
Biopsy-proven recurrent pMMR EC following surgery alone or de novo unresectable... [+13]
Patients who are currently in or have participated in a study of an investigatio... [+24]